Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 May 11;18:68. doi: 10.1186/s12883-018-1066-8

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s). 2018

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

PMC Copyright notice

Fig. 2 — Time to sustained EDSS progression by ≥4 versus 0 active T2 lesions at 6 months. a Placebo/delayed treatment group; b IFN β-1a 22 μg SC tiw group; c IFN β-1a 44 μg SC tiw group. A Cox proportional hazards model, adjusted for number of relapses in the previous 2 years, age, baseline EDSS score, and baseline burden of disease, was used to estimate hazard ratios and p values. p values are for time to first progression over 4 years. CI: confidence interval; EDSS: Expanded Disability Status Scale; IFN β-1a: interferon beta-1a; SC: subcutaneously; tiw: three times weekly